882670-69-1

Basic information

• Product Name: 5-AMINO-2-METHYLPHENYLBORONIC ACID, PINACOL ESTER
• Synonyms: 5-AMINO-2-METHYLPHENYLBORONIC ACID, PINACOL ESTER;4-Methyl-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenylamine;4,4,5,5-TetraMethyl-2-(5-aMino-2-Methylphenyl)-1,3,2-dioxaborolane;4-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline;5-Amino-2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-benzenamine;5-Amino-2-methylphenylboronic acid pinacol ester 97%;3-Hydroxy-2,3-dimethylbutan-2-yl hydrogen 5-amino-2-methylphenylboronate;4-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenamine
• CAS NO: 882670-69-1
• Molecular Formula: C₁₃H₂₀BNO₂
• Molecular Weight: 233.11
• Mol File: 882670-69-1.mol
• Article Data: 8

Chemical Properties

• Melting Point: 82-86°C
• Boiling Point: 366.2°C at 760 mmHg
• Flash Point: 175.3°C
• Appearance: /
• Density: 1.03
• Vapor Pressure: 1.49E-05mmHg at 25°C
• Refractive Index: 1.515
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 5.01±0.10(Predicted)
• CAS DataBase Reference: 5-AMINO-2-METHYLPHENYLBORONIC ACID, PINACOL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 5-AMINO-2-METHYLPHENYLBORONIC ACID, PINACOL ESTER(882670-69-1)
• EPA Substance Registry System: 5-AMINO-2-METHYLPHENYLBORONIC ACID, PINACOL ESTER(882670-69-1)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38-38-36
• Safety Statements: 26-36/37/39
• WGK Germany: 2
• Hazardous Substances Data: 882670-69-1(Hazardous Substances Data)

Usage

General Description

5-AMINO-2-METHYLPHENYLBORONIC ACID, PINACOL ESTER is a boronic acid derivative that contains an amino group and a methyl group attached to a phenyl ring. It is commonly used as a reagent in organic synthesis and medicinal chemistry, particularly in the development of pharmaceuticals and agrochemicals. The pinacol ester group in the molecule adds stability and solubility to the compound, making it easier to handle and store. This chemical is known for its ability to form strong and selective bonds with other molecules, making it a valuable tool in the creation of new compounds with specific properties and applications.

InChI:InChI=1/C13H20BNO2/c1-9-6-7-10(15)8-11(9)14-16-12(2,3)13(4,5)17-14/h6-8H,15H2,1-5H3

Upstream product

• 35944-64-0 3-iodo-4-methylaniline 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 882670-97-5 6-(5-amino-2-methylphenyl)quinazolin-2-amine 
• 1188410-30-1 cyclopropanesulfonic acid [4-methyl-3-(4,4,5,5-tetramethyl-[1,3,2]-dioxaborolan-2-yl)-phenyl]-amide 
• 882679-35-8 Cyclopropanecarboxylic acid [4-methyl-3-(4,4.5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-amide 
• 1207877-85-7 4-methyl-3-(6-(morpholinomethyl)pyridin-3-yl)aniline 
• 1207877-81-3 4-methyl-3-(5-(morpholinomethyl)pyridin-2-yl)aniline 
• 1207878-12-3 4-methyl-3-(6-(5-methyl-1,3,4-oxadiazol-2-yl)pyridin-3-yl)aniline 
• 1207878-24-7 3-(5-ethylpyridin-2-yl)-4-methylaniline 
• 1238376-59-4 3-isoquinolin-7-yl-4-methylaniline 

Relevant articles and documents

NEW COMPOUND

PROBLEM TO BE SOLVED: To provide a new compound that does not have structural similarity to ceramide and has excellent CERT inhibitory activity. SOLUTION: The present invention provides a new compound of structural formula (I). A bond group -X- is cis-cyclopropyl-, R1, R2, R3, R4, and R5 independently represent a hydrogen atom, a halogen atom, a linear or branched C1-C8 alkyl group that may have a halogen atom, or OR6. SELECTED DRAWING: Figure 1 COPYRIGHT: (C)2020,JPOandINPIT

NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS

The present invention discloses compounds according to Formula I: wherein R1, R2, R3, R4, L, and X are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical

EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER

The present invention is directed to compounds of generic formula (I) which are inhibitors of ephrin A4. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases regulated by the EphA4 RTK signaling, such as neurological and neurodegenerative disorders and cancer.